CEO Problems

Recently, I was talking to a CEO of a company I’m on the board of. We were discussing a problem in the category of something new Is fucked up in my world every day He gave me a great idea. He apparently plays a game with his young (I think around 10 years old) daughter. When they are sitting around in the evening, she occasionally says “Daddy, give me a CEO problem.” He does, she thinks about it a little, and then gives him a solution. He suggested to me that this often helps break him out of whatever thought rut he is in given how wacky and creative the answers typically are. Unfortunately, I don’t have a daughter (or a son). While I have two golden retrievers and I’m a practitioner of rubber duck debugging, I don’t think this works as well as what my friend is
Continue reading "CEO Problems"

Micro-learning app Blinkist attracts $18.8 mln Series C

Berlin-based Blinkist, a micro-learning app and platform, has raised $18.8 million in Series C funding. Insight Venture Partners led the round. PRESS RELEASE Berlin, 20 June 2018 – Blinkist, the micro-learning app and platform providing personal and professional development, today announces it has raised a Series C round of $18.8 million, led by Insight Venture Partners, with participation from existing investors Greycroft, IBB Bet and e.ventures, to expand its global operations. The company, which boasts an international network of over 6 million users, will use the funding to grow its Berlin-based team, establish Country Managers for individual markets, scale its international customer base, and continue to improve a product which is increasingly popular with time-poor, and information-hungry young professionals. Blinkist is currently available in English and German, but is planning to use the investment to strengthen its footprint across the globe and increase localised efforts in
Continue reading "Micro-learning app Blinkist attracts $18.8 mln Series C"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

Macy’s takes minority stake in VC-backed B8ta

Macy’s has acquired a minority stake in B8ta, a technology-powered retailer. No financial terms were disclosed. B8ta’s backers include TriplePoint Capital, Khosla Ventures, Fifth Wall Ventures, Macerich and Eniac Ventures. PRESS RELEASE NEW YORK–(BUSINESS WIRE)–Macy’s (NYSE:M) today announced an evolution of its commercial partnership with technology powered retailer b8ta. As part of its strategic focus on enhancing the in-store customer experience, the company will leverage b8ta’s best-in-class software platform to scale The Market @ Macy’s, becoming strategic partners in this ‘retail-as-a-service’ model. The Market @ Macy’s is the company’s experiential retail concept launched earlier this year. Macy’s has also acquired a minority equity stake in b8ta. “Macy’s is in the experience business. We’re always looking for new formats that allow our customers to discover and connect with our products and services in-store in a way that drives engagement with our brand,” said Hal Lawton, president of Macy’s. “We’re pleased to
Continue reading "Macy’s takes minority stake in VC-backed B8ta"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"

VC-backed Imara appoints new CEO

Cambridge, Massachusetts-based Imara Inc, a clinical-stage biopharmaceutical company, has named Dr. Rahul D. Ballal as CEO. Previously, Ballal was at Northern Biologics and Versant Ventures where he was chief business officer and an entrepreneur-in-residence, respectively. Imara is backed by New Enterprise Associates, Pfizer Venture Investments, Lundbeckfond Ventures, Bay City Capital and Alexandria Venture Investments. PRESS RELEASE CAMBRIDGE, Mass.–(BUSINESS WIRE)–Imara Inc., a clinical stage biopharmaceutical company, today announced that Rahul D. Ballal, Ph.D., has joining as its new Chief Executive Officer (CEO). Dr. Ballal comes to Imara with more than 15 years of life sciences experience and will help drive important expansion as the company’s investigational medicine for sickle cell disease, IMR-687, advances through mid- and late-stage clinical trials. Throughout his career, Dr. Ballal has demonstrated a track record of success in business development, strategic partnerships, venture capital, and company financing. Dr. Ballal will succeed Imara’s founder
Continue reading "VC-backed Imara appoints new CEO"